/
PRFX
$1.41-$0.10 (-6.62%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$4.6M
3M shares
52-week range
$1.28 – $17.95
1% from low
Exchange
NASDAQ
CS
Borrow rate
410.11%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-3430.59
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $86.0K | $0 | $0 | $17.0K |
| Cost of revenue | $0 | $1.0K | $0 | $7.0K | $15.0K | $15.0K | $16.0K | $844.0K |
| Gross profit | $0 | −$1.0K | $0 | −$7.0K | $71.0K | −$15.0K | −$16.0K | −$827.0K |
| Gross margin | — | — | — | — | 82.6% | — | — | -4864.7% |
| R&D | $223.0K | $136.0K | $354.0K | $2.9M | $4.4M | $6.0M | $11.7M | $1.1M |
| Operating income | −$500.0K | −$689.0K | −$1.7M | −$7.2M | −$8.9M | −$9.6M | −$14.7M | −$5.0M |
| EBITDA | $0 | −$688.0K | −$1.7M | −$7.2M | −$8.8M | −$9.6M | −$14.6M | −$4.2M |
| Net income | −$828.0K | −$1.8M | −$4.1M | −$7.2M | −$8.8M | −$9.3M | −$14.6M | −$4.8M |
| Net margin | — | — | — | — | -10223.3% | — | — | -28458.8% |
| EPS (diluted) | -1208.00 | -1552.86 | -2076.30 | -4430.82 | -4948.02 | -4283.23 | -804.00 | -7.47 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $10M | $-176.40 | $-176.40–$-176.40 | 1 |
| 2027 | $11M | $-129.60 | $-129.60–$-129.60 | 1 |
| 2028 | $37M | $19.20 | $19.20–$19.20 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$6.40
Price
$1.41
Implied upside
+354%
Peer comparison
PRF Technologies Ltd. Ordinary Shares
PRF Technologies Ltd is a a diversified platform spanning speciality pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics. PRF Technologies focuses on pharmaceutical therapies that emphasize reformulation and sustained-release drug-delivery technologies and AI-driven energy analytics. PRF-110, the company's lead product, is based on the local anesthetic ropivacaine and targets the postoperative pain relief market. The company has two operating segments composed of the Clinical Development segment, which facilitates the development of potential new drug compounds, and the Solar segment, which comprises the design and development of the company's intellectual property and the sale related service offerings.
www.painreform.com- Employees
- 6
- IPO / List date
- Sep 1, 2020
Held by traders on TradeandTell
No one on the platform currently holds PRFX.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in PRFX as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-02-06 | 1-for-5reverse |
| 2024-11-21 | 1-for-4reverse |
| 2024-09-09 | 1-for-6reverse |
| 2023-07-03 | 1-for-10reverse |
Recent trades on TradeandTell
No one on the platform has traded PRFX yet.
